WASHINGTON, Aug. 5, 2021 /PRNewswire/ -- The
Antimicrobials Working Group (AWG) announced today the addition of
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition
of companies with the mission to combat drug resistant infections
and spur life-saving innovations. This new addition brings AWG's
membership to 13 antimicrobial drug companies.
Acurx is a clinical stage biopharmaceutical company developing a
new class of antibiotics for infections caused by bacteria listed
as priority pathogens by the World Health Organization (WHO),
Centers for Disease Control and Prevention (CDC), and Food and Drug
Administration (FDA). Their lead product candidate, ibezapolstat,
is a first-in-class of a new class of DNA pol IIIC inhibitors which
is in Phase 2 clinical development to treat C. difficile
Infection (CDI). Ibezapolstat is the first antibiotic candidate
intended to work by blocking the DNA Pol IIIC enzyme, the enzyme
necessary for replication of the DNA of the C. difficile
"We are delighted to have Acurx join AWG and add their voice to
our mission to improve the antimicrobial drug and device
environment to provide doctors and patients with innovative
treatment options for difficult to treat infectious diseases," said
Ted Schroeder, Chief Executive
Officer of Nabriva Therapeutics and Chairman of AWG. "Through the
collective power of our membership, AWG will continue to engage
with key legislators and stakeholders to drive public policy that
will stabilize the fragile antimicrobial ecosystem, enable
appropriate patient access to novel products, and spur much-needed
research and development to help combat the growing threat of
antimicrobial resistance. We look forward to working with Acurx to
accomplish these goals."
Bob DeLuccia, Executive Chairman
of Acurx, stated: "Antibiotic-resistant Gram-positive infections
are substantial societal, public health, and economic burdens
worldwide. Methicillin-Resistant Staphylococcus
aureus (MRSA) alone accounts for more than half of the
infections in US-hospitalized patients, more than any other
category of pathogens, including the most problematic serious
Gram-negative infections combined. He further stated: "Acurx is
pleased to join the AWG and support its efforts to improve the
regulatory, investment and commercial environment for successful
antimicrobial drug development and commercialization, thereby
ensuring preparedness for the next pandemic, antimicrobial
resistance, for the benefit of patients worldwide."
All pharmaceutical and biotechnology companies developing new
antimicrobial therapeutics and diagnostic devices are eligible for
consideration of membership in AWG. If you are interested in
learning more about becoming a member of AWG, please contact us
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical
company focused on developing new antibiotics for difficult to
treat infections. The Company's approach is to develop antibiotic
candidates that target the DNA polymerase IIIC enzyme. Its R&D
pipeline includes antibiotic product candidates that target
Gram-positive bacteria, including Clostridioides difficile,
methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistant Enterococcus (VRE) and drug-resistant
Streptococcus pneumoniae (PRSP).
For more information, please
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging infectious disease companies. Today, AWG
is comprised of thirteen antimicrobials companies: Acurx
Pharmaceuticals, Inc. (NASDAQ: ACXP), Cidara Therapeutics Inc.
(NASDAQ: CDTX), , Crestone, Inc., Entasis Therapeutics Inc.,
Iterum Therapeutics Ltd. (NASDAQ: ITRM), Melinta Therapeutics
Inc. (NASDAQ: MLNT), Nabriva Therapeutics US Inc.
(NASDAQ: NBRV), Paratek Pharmaceuticals Inc.
(NASDAQ: PRTK), Qpex Biopharma, Inc., SCYNEXIS Inc.
(NASDAQ: SCYX), Summit Therapeutics plc (NASDAQ: SMMT)
(AIM: SUMM), UTILITY therapeutics Ltd., and Venatorx
For more information,
About The Conafay Group
The Conafay Group, led by Stephen R. Conafay, Principal, is
a life-sciences government relations firm based in Washington
D.C. that serves as Washington counsel and coalition
manager for AWG.
For more information, visit: www.conafaygroup.com
View original content to download
SOURCE Antimicrobials Working Group (AWG)